What's Happening?
The Centers for Medicare & Medicaid Services (CMS) has released draft guidance for the implementation of the Maximum Fair Price (MFP) in 2028 under the Medicare Drug Price Negotiation Program. This guidance, published on July 16, 2026, is part of the ongoing
efforts to manage drug pricing under the Inflation Reduction Act. CMS is seeking public comments on this draft, with a deadline set for September 18, 2026. The proposed rule also includes changes to the Part D inflation rebate program, such as defining the 'first marketed date' for drugs. Additionally, the 2027 Physician Fee Schedule proposed rule requires 340B covered entities to submit Part D claims data, aiming to improve the accuracy of rebate calculations.
Why It's Important?
The draft guidance and proposed rules are significant as they aim to control drug prices, a major concern for Medicare beneficiaries and the healthcare system. By soliciting public comments, CMS is engaging stakeholders in shaping policies that could lead to more affordable medications. The requirement for 340B entities to submit claims data could enhance transparency and ensure fair pricing practices. These measures are part of broader healthcare reforms intended to reduce costs and improve access to essential medications for millions of Americans.
What's Next?
Stakeholders, including pharmaceutical companies, healthcare providers, and patient advocacy groups, are expected to submit their comments on the draft guidance by the September deadline. The feedback will likely influence the final version of the guidance. Additionally, the proposed changes to the Physician Fee Schedule will undergo further review, with potential adjustments based on stakeholder input. The outcomes of these processes will shape the future landscape of drug pricing and reimbursement under Medicare.
